ANDA 91414, held by Aiping Pharmaceutical. Montelukast Sodium.
As of Nov 21, 2026, ANDA 91414 (Montelukast Sodium), held by Aiping Pharmaceutical, was first approved by FDA on Aug 3, 2012, with 9 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 3, 2012 | Original application | Approved |
| Montelukast SodiumEQ 4MG BASE · tablet, chewable;oral | Montelukast Sodium | Discontinued |
| Montelukast SodiumEQ 5MG BASE · tablet, chewable;oral | Montelukast Sodium | Discontinued |
| Jan 19, 2022 | Supplement 17Labeling · Standard review | Approved | None posted |
| Sep 4, 2020 | Supplement 14Labeling · Standard review | Approved | None posted |
| Sep 4, 2020 | Supplement 16Labeling · Standard review | Approved | None posted |
| Oct 1, 2019 | Supplement 11Labeling · Standard review | Approved | None posted |
| Jul 26, 2018 | Supplement 10Labeling · Standard review | Approved | None posted |
| May 4, 2015 | Supplement 8Labeling · Standard review | Approved | None posted |
| May 4, 2015 | Supplement 9Labeling · Standard review | Approved | None posted |
| Jun 26, 2013 | Supplement 6Labeling · Standard review | Approved | None posted |
| Jan 28, 2013 | Supplement 4Labeling · Standard review | Approved | None posted |
| Aug 3, 2012 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters